MannKind | Kostnadene For Salg



Cost Of Sales Endring Dato
Adma Biologics USD 54.22M 5.96M 2024-12
Dynavax Technologies USD 13.41M 326K 2024-12
Eli Lilly USD 2.4B 233M 2024-12
Halozyme Therapeutics USD 42.06M 7.37M 2024-12
Insmed USD 26.15M 4.98M 2024-12
MacroGenics USD 5.49M 3.62M 2024-12
MannKind USD 17.6M 119K 2024-12
Merck USD 3.71B 181M 2024-12
Novo Nordisk DKK 11.31B 1.03B 2024-09
Pfizer USD 5.65B 781M 2024-12
Sanofi EUR 4.08B 675M 2024-09
Xencor 10.71M 4.56M 2024-09



MannKind Kostnadene For Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2025.